Biosimilars: A multidisciplinary perspective

Clinical Therapeutics

Volumn 38, Issue 5, 2016, Pages 1238-1249

  Khraishi, Majed ^a   Stead, David ^b   Lukas, Milan ^c   Scotte, Florian ^d   Schmid, Holger ^e  

^a MEMORIAL UNIVERSITY OF NEWFOUNDLAND   (Canada)

^b Pharmaceutical Market Support Group   (United Kingdom)

^c CHARLES UNIVERSITY   (Czech Republic)

^d HÔPITAL EUROPÉEN GEORGES POMPIDOU   (France)

^e LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

Author keywords

arthritis; biosimilars; Inflammatory Bowl Disease (IBD); Nephrology; pharmacovigilance; safety

Indexed keywords

BIOSIMILAR AGENT; MONOCLONAL ANTIBODY;

CLINICAL EFFECTIVENESS; CLINICAL PRACTICE; DRUG SAFETY; DRUG SURVEILLANCE PROGRAM; GASTROENTEROLOGY; HUMAN; NEPHROLOGY; ONCOLOGY; REVIEW; RHEUMATOLOGY; EUROPE; RISK ASSESSMENT;

ANTIBODIES, MONOCLONAL; BIOSIMILAR PHARMACEUTICALS; EUROPE; HUMANS; PHARMACOVIGILANCE; RISK ASSESSMENT;

EID: 84960510635     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/j.clinthera.2016.02.023     Document Type: Article

References (60)

1. M.S. Epstein, E.D. Ehrenpreis, and P.M. Kulkarni Biosimilars: the need, the challenge, the future: the FDA perspective Am J Gastroenterol 109 2014 1856 1859
2. GaBI Online - Generics and Biosimilars Initiative. FDA advisers recommend approval of filgrastim biosimilar. Mol: Pro Pharma Communications International. 2015;2015.
3. A.D. Zelenetz, I. Ahmed, E.L. Braud, and et al. NCCN Biosimilars White Paper: regulatory, scientific, and patient safety perspectives J Natl Compr Cancer Netw 9 Suppl 4 2011 S1 22
4. D. Niederwieser, and S. Schmitz Biosimilar agents in oncology/haematology: from approval to practice Eur J Haematol 86 2011 277 288
5. E. Choy, and I.A. Jacobs Biosimilar safety considerations in clinical practice Semin Oncol 41 Suppl 1 2014 S3 14
6. T. Hlavaty, and J. Letkovsky Biosimilars in the therapy of inflammatory bowel diseases Eur J Gastroenterol Hepatol 26 2014 581 587
7. World Health Organisation. Guidelines on Evaluation of Similar Biotherapeutic Products (SBPs). WHO Expert Committee on Biological Standardization, Sixtieth report (19-23 October 2009) WHO Technical Report Series No. 977, 2013 - Annex 2 2013.
8. P. Hurley, J. Boren, and C. Congiatu Challenges in global biosimilar development: A regulatory perspective Contract Pharma 2015
9. European Commission. What you need to know about biosimilar medicinal products. 2013.
10. European Medicines Agency. Guideline on similar biological medicinal products. EMA/CHMP/437/04 Rev 1. Committee for Medicinal Products for Human Use (CHMP). 2014.
11. International Conference on Harmonisation (ICH). ICH Harmonised Tripartite Guideline. Comparability of biotechnological/biological products subject to changes in their manufacturing process. Q5E. 2004.
12. A. Mikhail, and M. Farouk Epoetin biosimilars in Europe: five years on Adv Ther 30 2013 28 40
13. K. McKeage A review of CT-P13: an infliximab biosimilar BioDrugs 28 2014 313 321
14. M.L. Davis-Ajami, J. Wu, K. Downton, and et al. Epoetin zeta in the management of anemia associated with chronic kidney disease, differential pharmacology and clinical utility Biologics 8 2014 155 167
15. European Medicines Agency (EMA). Epoetin alfa Hexal. EPAR Scientific Discussion. 2007.
16. European Medicines Agency (EMA). Retacrit. EPAR Scientific Discussion. 2007.
17. European Medicines Agency, Committee for Medicinal Products for Human Use (CHMP). Assessment report: Inflectra (infliximab). 2013.
18. F. Sorgel, U. Thyroff-Friesinger, A. Vetter, and et al. Bioequivalence of HX575 (recombinant human epoetin alfa) and a comparator epoetin alfa after multiple intravenous administrations: an open-label randomised controlled trial BMC Clin Pharmacol 9 2009 10
19. V. Kirkov, V. Dimitrova, M. Siebert-Weigel, and et al. Evaluation of the pharmacokinetics of two recombinant human erythropoietin preparations: epoetin zeta and epoetin alfa. 1st Communication: A monocentric, open, randomized, single dose, two-period crossover trial in healthy volunteers Arzneimittelforschung 58 2008 215 219
20. V. Kirkov, V. Dimitrova, M. Siebert-Weigel, and et al. Evaluation of the pharmacokinetics of two recombinant human erythropoietin preparations: epoetin zeta and epoetin alfa. 2nd Communication: A monocentric, double-blind, randomized, single dose, three-period crossover trial in healthy volunteers Arzneimittelforschung 58 2008 220 224
21. M. Haag-Weber, A. Vetter, and U. Thyroff-Friesinger Therapeutic equivalence, long-term efficacy and safety of HX575 in the treatment of anemia in chronic renal failure patients receiving hemodialysis Clin Nephrol 72 2009 380 390
22. S. Krivoshiev, V.V. Todorov, J. Manitius, and et al. Comparison of the therapeutic effects of epoetin zeta and epoetin alpha in the correction of renal anaemia Curr Med Res Opin 24 2008 1407 1415
23. V. Wizemann, B. Rutkowski, C. Baldamus, and et al. Comparison of the therapeutic effects of epoetin zeta to epoetin alfa in the maintenance phase of renal anaemia treatment Curr Med Res Opin 24 2008 625 637
24. W. Park, P. Hrycaj, S. Jeka, and et al. A randomised, double-blind, multicentre, parallel-group, prospective study comparing the pharmacokinetics, safety, and efficacy of CT-P13 and innovator infliximab in patients with ankylosing spondylitis: the PLANETAS study Ann Rheum Dis 72 2013 1605 1612
25. D.H. Yoo, P. Hrycaj, P. Miranda, and et al. A randomised, double-blind, parallel-group study to demonstrate equivalence in efficacy and safety of CT-P13 compared with innovator infliximab when coadministered with methotrexate in patients with active rheumatoid arthritis: the PLANETRA study Ann Rheum Dis 72 2013 1613 1620
26. G. Castaneda-Hernandez, Z. Szekanecz, E. Mysler, and et al. Biopharmaceuticals for rheumatic diseases in Latin America, Europe, Russia, and India: Innovators, biosimilars, and intended copies Joint Bone Spine 81 2014 471 477
27. C. Baldamus, S. Krivoshiev, M. Wolf-Pflugmann, and et al. Long-term safety and tolerability of epoetin zeta, administered intravenously, for maintenance treatment of renal anemia Adv Ther 25 2008 1215 1228
28. T.T. Hansel, H. Kropshofer, T. Singer, and et al. The safety and side effects of monoclonal antibodies Nat Rev Drug Discov 9 2010 325 338
29. F.R. Brennan, A. Cauvin, J. Tibbitts, and A. Wolfreys Optimized nonclinical safety assessment strategies supporting clinical development of therapeutic monoclonal antibodies targeting inflammatory diseases Drug Dev Res 75 2014 115 161
30. J. Rossert, N. Casadevall, and K.U. Eckardt Anti-erythropoietin antibodies and pure red cell aplasia J Am Soc Nephrol 15 2004 398 406
31. W. Jelkmann Biosimilar epoetins and other "follow-on" biologics: update on the European experiences Am J Hematol 85 2010 771 780
32. L. Endrenyi, C. Chang, S.C. Chow, and L. Tothfalusi On the interchangeability of biologic drug products Stat Med 32 2013 434 441
33. H.C. Ebbers, M. Muenzberg, and H. Schellekens The safety of switching between therapeutic proteins Expert Opin Biol Ther 12 2012 1473 1485
34. B.G. Feagan, D. Choquette, S. Ghosh, and et al. The challenge of indication extrapolation for infliximab biosimilars Biologicals 42 2014 177 183
35. H. Lee Is extrapolation of the safety and efficacy data in one indication to another appropriate for biosimilars? AAPS J 16 2014 22 26
36. P. Putrik, S. Ramiro, T.K. Kvien, and et al. Inequities in access to biologic and synthetic DMARDs across 46 European countries Ann Rheum Dis 73 2014 198 206
37. S. Danese, G. Fiorino, and P. Michetti Viewpoint: knowledge and viewpoints on biosimilar monoclonal antibodies among members of the European Crohn's and Colitis Organization J Crohns Colitis 8 2014 1548 1550
38. S.K. Jung, K.H. Lee, J.W. Jeon, and et al. Physicochemical characterization of Remsima MAbs 6 2014 1163 1177
39. Yoon Suk J, Park DI, Kim YH, etal. Efficacy and safety of infliximab's biosimilar (REMSIMA)for IBD, 2015, Poster no. 540.
40. Gecse K, Farkas K, Lovasz B, etal. Biosimilar infliximab in inflammatory bowel diseases: first interim results from a prospective nation wide cohort 2015, Poster no. 540.
41. F. Bocquet, P. Paubel, I. Fusier, and et al. Biosimilar granulocyte colony-stimulating factor uptakes in the EU-5 markets: a descriptive analysis Appl Health Econ Health Policy 12 2014 315 326
42. L. Gesualdo, G. London, M. Turner, and et al. A pharmacoepidemiological study of the multi-level determinants, predictors, and clinical outcomes of biosimilar epoetin alfa for renal anaemia in haemodialysis patients: background and methodology of the MONITOR-CKD5 study Intern Emerg Med 8 2013 389 399
43. S.C. Palmer, V. Saglimbene, D. Mavridis, and et al. Erythropoiesis-stimulating agents for anaemia in adults with chronic kidney disease: a network meta-analysis Cochrane Database Syst Rev 12 2014 CD010590
44. C.L. Bennett, S. Jacob, J. Hymes, and et al. Anaphylaxis and hypotension after administration of peginesatide N Engl J Med 370 2014 2055 2056
45. K.H. Rak Tkaczuk, and I.A. Jacobs Biosimilars in oncology: from development to clinical practice Semin Oncol 41 Suppl 3 2014 S3 S12
46. P. Lammers, C. Criscitiello, G. Curigliano, and I. Jacobs Barriers to the Use of Trastuzumab for HER2+ Breast Cancer and the Potential Impact of Biosimilars: A Physician Survey in the United States and Emerging Markets Pharmaceuticals 7 2014 943 953
47. M. Michallet, E. Luporsi, P. Soubeyran, and et al. BiOsimilaRs in the management of anaemia secondary to chemotherapy in HaEmatology and Oncology: results of the ORHEO observational study BMC Cancer 14 2014 503
48. P. Gascon, M. Aapro, H. Ludwig, and et al. Background and methodology of MONITOR-GCSF, a pharmaco-epidemiological study of the multi-level determinants, predictors, and clinical outcomes of febrile neutropenia prophylaxis with biosimilar granulocyte-colony stimulating factor filgrastim Crit Rev Oncol Hematol 77 2011 184 197
49. IMS Institute for Healthcare Informatics. Assessing biosimilar uptake and competition in European markets. IMS Report. 2014. https://www.imshealth.com/files/web/IMSH%20Institute/Healthcare%20Briefs/Assessing-biosimilar-uptake-and-competition-in-European-markets.pdf. Accessed
50. E.M. Vital, J. Kay, and P. Emery Rituximab biosimilars Expert Opin Biol Ther 13 2013 1049 1062
51. F. Araujo, I. Cordeiro, F. Teixeira, and et al. Pharmacology of biosimilar candidate drugs in rheumatology: a literature review Acta Reumatol Port 39 2014 19 26
52. G. Fiorino, G. Girolomoni, G. Lapadula, and et al. The use of biosimilars in immune-mediated disease: A joint Italian Society of Rheumatology (SIR), Italian Society of Dermatology (SIDeMaST), and Italian Group of Inflammatory Bowel Disease (IG-IBD) position paper Autoimmun Rev 13 2014 751 755
53. D. Grabowski, B. Henderson, D. Lam, and et al. Attitudes towards subsequent entry biologics/biosimilars: A survey of Canadian rheumatologists Clin Rheumatol 34 2015 1427 1433
54. K. Papp, M. Bourcier, V. Ho, and et al. Preparing for subsequent entry biologics in dermatology and rheumatology in Canada J Cutan Med Surg 17 2013 340 346
55. G. Befrits The case for biosimilars - a payer's perspective GaBI J 2 2013 12
56. B. Wu, Y. Song, L. Leng, and et al. Treatment of moderate rheumatoid arthritis with different strategies in a health resource-limited setting: a cost-effectiveness analysis in the era of biosimilars Clin Exp Rheumatol 33 2011 20 26
57. P.W. Wojciechowski, H.I. Smit, M.M. Myers, and et al. Making changes to a biopharmaceutical manufacturing process during development and commercial manufacturing: The REMICADE® story A.A. Shukka, M.R. Etzel, S. Gadam, Process scale bioseparations for the biopharmaceutical industry 2007 Taylor & FrancisGroup Boca Raton, Florida 507 522
58. GaBI Online. Biosimilars approved in Europe. 2011. http://www.gabionline.net/Biosimilars/General/Biosimilars-approved-in-Europe. Accessed December 11, 2014
59. H. Mellstedt, D. Niederwieser, and H. Ludwig The challenge of biosimilars Ann Oncol 19 2008 411 419
60. Food and Drug Administration. Scientific considerations in demonstrating biosimilarity to a reference product. Guidance for industry. 2015. http://www.fda.gov/downloads/DrugsGuidanceComplianceRegulatoryInformation/Guidances/UCM291128.pdf.